EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR IN ENDOMETRIAL CANCER PATIENTS WITH METABOLIC DISORDERS
DOI:
https://doi.org/10.15407/exp-oncology.2023.01.044Keywords:
endometrial cancer, metabolic disorders, population and subpopulation composition of lymphocytes, programmed cell death receptorAbstract
Aim: To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders. Materials and Methods: Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were used to detect PD-L1 on monocytes. Results: In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation therapy were higher than in the control group. Conclusion: Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity.
References
Globocan 2018. Latest global cancer data. World Health Organization. 2018; https://www.who.int/cancer/PRGlobocanFinal.pdf.
Fedorenko ZP, Goulak LO, Gorokh YeL, et al. Cancer in Ukraine 2020–2021: incidence, mortality, prevalence and other relevant statistics. Bull Nat Cancer Reg Ukraine 2022: 23. Available at http://www.ncru.inf.ua/publications/BULL_23/index_e.htm
Laktionov KP, Nikolaienko LO, Berishvil AI. Metabolic syndrome and cancer of the organs of reproductive system. Cancer Female Reproductive System 2014; 2: 56–58. doi:org/10.17650/1994-4098-2014-0-2-56-58 (in Russian).
RoseDP,GracheckPJ,Vona-Davis L. The interactions of obesity, inflammation and insulin resistance in breast cancer. Cancers (Basel) 2015; 7: 2147–2168. doi: 10.3390/cancers7040883
Cai Y, Wang B, Xu W, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr Med Chem 2021; 28: 8755–8781. doi: 10.2174/0929867328666210705144456
Dull AM, Moga MA, Dimienescu OG, et al. Therapeutic approaches of resveratrol on endometriosis via anti-inflammatory and anti-angiogenic pathways. Molecules 2019; 24: 667. doi: 10.3390/molecules24040667
Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide. Blood 2012; 120: 1412–1421. doi: 10.1182/blood-2012-02-411678
Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore) 2017; 96: e6369. doi:10.1097/MD.0000000000006369
Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146: 15–24. doi:10.1007/s10549-014-2988-5
Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget 2017; 8: 31347–31354. doi:10.18632/oncotarget.15532
Brown JA, Dorfman DM, Ma F-R, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257–1266. doi: 10.4049/jimmunol.170.3.1257
Sorochan PP, Gomakova IA, Prokhach NE, et al. Changes in subpopulation composition of lymphocytes following radiotherapy of patients with cancer of corpus uteri with obesity. Exp Clin Med 2018; 2-3: 7961–7965 (in Ukrainian).
Rosignoli G, Lim CH, Bower M, et al. Programmed death (PD)–1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol 2009; 157: 90–97. doi:10.1111/j.1365-2249.2009.03960.x
Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366: 2517–2519. doi: 10.1056/NEJMe1205943
Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013; 98: 953–963. doi: 10.3324/haematol.2012.077537
Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003; 33: 2706–2716. doi: 10.1002/eji.200324228
Hudson K, Cross N, Jordan-Mahy N, et al. The extrinsic and intrinsic roles of PD-L1 and Its Receptor PD-1: Implications for immunotherapy treatment. Front Immunol 2020; 11: 568931. doi: 10.3389/fimmu.2020.568931
Sun C, Mezzada R Schumacher TN. Regulation and function of the PDL1 checkpoint. Immunity 2018; 48: 434–452. doi: 10.1016/j.immuni.2018.03.014
Thompson RH. Dong H. Lohse CM. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 1757–1761. doi: 10.1158/1078-0432.CCR-06-2599
Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146: 15–24. doi: 10.1007/s10549-014-2988-22
Hansen MV, Rosenberg J, Gögenur I. Lack of circadian variation and reduction of heart rate variability in women with breast cancer undergoing lumpectomy: a descriptive study. Breast Cancer Res Treat 2013; 140: 317–322. doi:10.1007/s10549-013-2631-x
Dutta D, Ghosh S, Pandit K, et al. Leptin and cancer: Pathogenesis and modulation. Ind J Endocrinol Metab 2012; 16: S596–S600. doi:10.4103/2230-8210.105577
Saxena NK, Sharma D. Multifaceted leptin network: the molecular connection between obesity and breast cancer. J Mammary Gland Biol Neoplasia 2013; 18: 309–320. doi:10.1007/s10911-013-9308-2
Candelaria PV, Rampoldi A, Harbuzariu A, Gonzalez-Perez RR. Leptin signaling and cancer chemoresistance: Perspectives. World J Clin Oncol 2017; 8: 106–119. doi:10.5306/wjco.v8.i2.106
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
